Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
No injections are needed
H.HymanT.DikicI
This drug was first approved for treating type 2 diabetes under the name Mounjaro, and late last year it was approved for weight loss as Zepbound
Reliable supply arrangements help support future growth while minimizing disruptions caused by inconsistent availability
Impact of new GLP-1 entrants, including anticipated oral formulations expected to enter the market in 2026, which may materially change price points and member experience
Consistent with the base-case analysis, sensitivity analyses demonstrated that using GLP-1RAs versus insulin was either cost-saving or cost-effective, except for the analyses where the treatment effectiveness was estimated based on the AT scenario in the second and third sensitivity analyses, showing that a GLP-1RA versus insulin therapy was not cost-effective for averting one case of all-cause death from the payer perspective
US$ 28.67
US$ 25.08
US$ 24.17
